Completed PHASE2 INTERVENTIONAL NCT00197457

Pepsinogens as the Early Marker of H. Pylori Eradication

Serum Pepsinogens as an Early Diagnostic Marker of H. Pylori Eradication

Sponsor: Hamamatsu University

Conditions Duodnal Ulcer Gastric Ulcer H. Pylori Infection

Interventions serum pepsinogen urea breath test

Updated 5 times since 2017 Last updated: Jan 31, 2006 Started: Jun 30, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Duodnal Ulcer and Gastric Ulcer and is currently completed. Hamamatsu University leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hamamatsu University

Data source: Hamamatsu University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamamatsu, Japan